MIT ILP's Annual Wuxi, China Symposium will be held on January 7, 2019 hosted by MIT and Wuxi City.
Symposium Theme & areas of interest: IoT, Advanced Manufacturing, New Energy, New Materials, Life Science, Blockchain.
Does your startup have a solution for urgent Covid-19 needs? Ideally they should be validated to work and demonstrate feasibility to scale. And could contacts to corporates help you scale up? MIT Startup Exchange is looking to help you connect.
Seeking 4-6 startups to participate in the ILP Beijing Virtual Symposium on November 5, 2020.
P&G is looking for new approaches and technologies that can help them to address key business challenges/opportunities.
AI Driven Bloodless Blood Tests Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx GPx: https://gpx.ai/
In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has proven effective in reducing heart failure readmissions, but its use remains limited.
To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.
Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto University, Kobe University, and Kochi University.
Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology) and to assess the potential for providing algorithm-based services for heart failure patients within Japan.
Japanese multinational technology company in office equipment, optical systems for industrial use, and diagnostic imaging systems seeks startups for new innovative technologies, devices and systems.
Murata is seeking startups to trial its innovative cell fractionation filter, CELLNETTA, to identify key challenges this product can solve.
A leading Japanese manufacturer of functional materials -- including in the fields of electronics, automotive, housing, infrastructure, environmental and medical -- is seeking startups to collaborate with for the design and development of new products using ambient curable adhesive sheet.
STEX25 Accelerator Startups - July 21